{
    "cancer_info": {
        "cancer_name": "Multiple Myeloma"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "CBC",
            "Peripheral blood smear",
            "Serum creatinine/BUN",
            "Electrolytes",
            "Calcium",
            "LDH",
            "β2-microglobulin",
            "Quantitative immunoglobulins",
            "SPEP/SIFE",
            "Serum free light chains (FLC)",
            "24-hour urine UPEP/UIFE/total protein",
            "Bone marrow aspiration/biopsy",
            "FISH panel (del(17p), t(4;14), t(11;14), t(14;16), 1q21 gain/amp, 1p del)",
            "Flow cytometry",
            "NGS for MRD testing",
            "FDG PET/CT",
            "Whole-body low-dose CT",
            "Whole-body MRI",
            "Skeletal survey (if advanced imaging unavailable)",
            "NT-proBNP/BNP (cardiac involvement)",
            "VEGF/IL-6 (POEMS)",
            "Frailty assessment",
            "Nerve conduction studies (NCS)",
            "Electromyography (EMG)",
            "Anti-MAG antibodies",
            "MYD88 L265P/CXCR4 mutation testing",
            "Endocrine hormone panel",
            "Bone lesion biopsy",
            "Renal biopsy (if proteinuria >1g/day, eGFR <60 mL/min, or acute kidney injury)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Newly Diagnosed",
            "risk_group": "Transplant-Eligible",
            "treatment_plans": [
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "All",
                    "plan_name": "D-RVd",
                    "plan_details": "Daratumumab + lenalidomide/bortezomib/dexamethasone",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "All",
                    "plan_name": "KRd",
                    "plan_details": "Carfilzomib + lenalidomide/dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other regimen"
                },
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "All",
                    "plan_name": "Isa-VRd",
                    "plan_details": "Isatuximab + bortezomib/lenalidomide/dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other regimen"
                }
            ]
        },
        {
            "staging_criteria": "Newly Diagnosed",
            "risk_group": "Non-Transplant-Eligible",
            "treatment_plans": [
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "All",
                    "plan_name": "D-Rd",
                    "plan_details": "Daratumumab + lenalidomide/dexamethasone",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "Non-frail ≥80 years",
                    "plan_name": "Isa-VRd",
                    "plan_details": "Isatuximab + bortezomib/lenalidomide/dexamethasone",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "Frail patients",
                    "plan_name": "VRd-lite",
                    "plan_details": "Reduced-dose bortezomib/lenalidomide/dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Maintenance Therapy",
            "risk_group": "Standard Risk",
            "treatment_plans": [
                {
                    "treatment_line": "Maintenance",
                    "patient_subgroup": "Post-HCT or non-HCT",
                    "plan_name": "Lenalidomide",
                    "plan_details": "Continuous lenalidomide therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Maintenance Therapy",
            "risk_group": "High Risk",
            "treatment_plans": [
                {
                    "treatment_line": "Maintenance",
                    "patient_subgroup": "Post-HCT",
                    "plan_name": "Carfilzomib-Lenalidomide",
                    "plan_details": "Carfilzomib + lenalidomide",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Maintenance",
                    "patient_subgroup": "Post-HCT",
                    "plan_name": "Daratumumab-Lenalidomide",
                    "plan_details": "Daratumumab + lenalidomide",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory",
            "risk_group": "After 1-3 Prior Lines",
            "treatment_plans": [
                {
                    "treatment_line": "Therapy",
                    "patient_subgroup": "Anti-CD38 Refractory",
                    "plan_name": "DPd",
                    "plan_details": "Daratumumab + pomalidomide/dexamethasone",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Therapy",
                    "patient_subgroup": "Anti-CD38 Refractory",
                    "plan_name": "KRd",
                    "plan_details": "Carfilzomib + lenalidomide/dexamethasone",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Therapy",
                    "patient_subgroup": "All",
                    "plan_name": "CAR T-Cell Therapy",
                    "plan_details": "Ciltacabtagene autoleucel (after 1 line) or Idecabtagene vicleucel (after 2 lines)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory",
            "risk_group": "After ≥3 Prior Lines",
            "treatment_plans": [
                {
                    "treatment_line": "Therapy",
                    "patient_subgroup": "BCMA-naïve",
                    "plan_name": "Bispecific Antibodies",
                    "plan_details": "Elranatamab, talquetamab, or teclistamab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Therapy",
                    "patient_subgroup": "Triple-class refractory",
                    "plan_name": "Selinexor-Dexamethasone",
                    "plan_details": "Selinexor + dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other regimen"
                }
            ]
        },
        {
            "staging_criteria": "Special Populations",
            "risk_group": "Renal Impairment",
            "treatment_plans": [
                {
                    "treatment_line": "Therapy",
                    "patient_subgroup": "Acute Kidney Injury (Cr >2 mg/dL)",
                    "plan_name": "Bortezomib-based",
                    "plan_details": "Hydration + pulse dexamethasone + bortezomib/daratumumab regimens",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Therapy",
                    "patient_subgroup": "Dialysis-dependent",
                    "plan_name": "Lenalidomide adjustment",
                    "plan_details": "5 mg post-dialysis with dose adjustments based on CrCl",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Required adjustment"
                }
            ]
        },
        {
            "staging_criteria": "Special Populations",
            "risk_group": "POEMS Syndrome",
            "treatment_plans": [
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "Isolated lesion",
                    "plan_name": "Radiation Therapy",
                    "plan_details": "40-50 Gy radiation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "Disseminated disease",
                    "plan_name": "Len/Dex ± Dara",
                    "plan_details": "Lenalidomide/dexamethasone ± daratumumab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "del(17p), t(4;14), t(14;16), 1q21 gain/amp: Inferior OS/PFS (prognostic)",
            "Elevated LDH, β2-microglobulin, FLC ratio ≥100: Indicate high tumor burden (prognostic)",
            "t(11;14): Predicts venetoclax sensitivity (therapeutic)",
            "BCMA Expression: Required for CAR T-cell therapies and bispecific antibodies (therapeutic)",
            "MRD negativity: Correlates with prolonged PFS/OS (prognostic)",
            "VEGF levels: Diagnostic/therapeutic target in POEMS syndrome",
            "MYD88 L265P mutation: Associates with IgM MGNS/Waldenström macroglobulinemia"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：多发性骨髓瘤.txt"
}